Fill 1 Return To RT

The Era of Anti-VEGF Biosimilars: Navigating the Treatment Paradigm for Retinal Vascular Diseases

Table of Contents

This activity is supported by an unrestricted educational grant from Regeneron.

November/December 2022 Supplement

The Era of Anti-VEGF Biosimilars: Navigating the Treatment Paradigm for Retinal Vascular Diseases

Share:

November/December 2022 Supplement cover

View Supplement